Nanobiotix Announces Significant Findings in Pancreatic Cancer Treatment
Nanobiotix has recently revealed the full results of a groundbreaking Phase 1 study focusing on JNJ-1900 (NBTXR3) and its effectiveness in treating pancreatic cancer. This study, conducted with a group of 22 patients suffering from locally advanced or borderline resectable pancreatic cancer, aims to add a new perspective to the current treatment landscape.
Key Study Outcomes and Implications
The results from the study showcase a favorable safety profile and the practical feasibility of injection. Notably, patients experienced a median overall survival of 23 months from their date of diagnosis, with compelling data indicating a median local progression-free survival of 13.3 months following radiation therapy. These findings suggest promising oncologic outcomes that could reshape standard treatment protocols.
Exploratory Biomarker Findings
The exploratory analyses uncovered intriguing links between increased circulating tumor mutational burden (cTMB) and improved local progression-free survival (LPFS) and overall survival (OS). Additionally, a significant 59% of patients exhibited normalization of CA19-9 levels, a biomarker commonly used to predict treatment outcomes, indicating a potential correlation with survival.
Future Directions for Therapy
Excitingly, the study has initiated a new cohort where standard-of-care chemotherapy such as capecitabine or 5-FU will be administered alongside radiotherapy-activated JNJ-1900 (NBTXR3). This innovative approach is encouraging and the recruitment for this segment is currently ongoing. Investigators emphasize that these results warrant further exploration in randomized trials.
The Urgent Need for Therapeutic Advancements
Pancreatic ductal adenocarcinoma is recognized for being particularly aggressive. Current therapies often fail to yield satisfactory results in patients with locally advanced or borderline resectable forms of this cancer. Given this context, Dr. Eugene Koay from MD Anderson remarks on the urgent need for new therapeutic innovations that can deliver substantial survival benefits with acceptable safety rates.
Collaboration and Expansion Efforts
Nanobiotix is engaged in a fruitful partnership with The University of Texas MD Anderson Cancer Center, driven by a shared ambition to innovate treatment approaches for patients with high unmet clinical needs. The results from this study not only inspire confidence in the potential of JNJ-1900 (NBTXR3) but also indicate its capacity to complement chemoradiation therapies.
Conference and Investor Relations
To discuss these results further, Nanobiotix has scheduled a conference call featuring their CEO, Laurent Levy. Participants can find details for the call on the company's website. Stakeholders are encouraged to listen in, as the insights shared will deepen understanding of the implications surrounding JNJ-1900 (NBTXR3).
About JNJ-1900 (NBTXR3)
JNJ-1900 (NBTXR3) represents a novel oncology innovation that utilizes functionalized hafnium oxide nanoparticles. When activated by radiotherapy, it aims to enhance tumor cell death and stimulate an adaptive immune response against cancer. This novel therapeutic strategy could be significant across various solid tumors, particularly when combined with immune checkpoint inhibitors.
About Nanobiotix
Founded in 2003 and headquartered in Paris, France, Nanobiotix is on the cutting edge of biotechnology, leveraging physics-based solutions to transform cancer treatment outcomes. With over 25 patents, the company’s focus remains on groundbreaking therapies aimed at improving the quality of life for patients worldwide.
Frequently Asked Questions
What is JNJ-1900 (NBTXR3)?
JNJ-1900 (NBTXR3) is a novel oncology product composed of nanoparticles that aim to enhance tumor cell death when activated by radiotherapy.
What were the key findings from the Phase 1 study?
The study revealed a median overall survival of 23 months and a median local progression-free survival of 13.3 months for patients treated with JNJ-1900 (NBTXR3).
Why is this study important?
This study addresses a significant unmet need in treatment for pancreatic cancer, aiming to improve survival rates in a particularly aggressive malignancy.
What are the next steps for JNJ-1900 (NBTXR3)?
Further evaluations in randomized studies are planned, particularly focusing on patients who will also receive standard-of-care chemotherapy.
How can investors learn more about Nanobiotix?
Investors can follow updates through the Nanobiotix website and participate in scheduled conference calls to remain informed about developments and results.
